biospecific antibodies

ASCO 2014: Doubling Down on Next-Gen Cancer Drugs
Motley Fool
Tue, 06/3/14 - 12:26 pm
ASCO
Roche
Amgen
blinatumomab
AstraZeneca
cancer
biospecific antibodies